Cochrane · systematic review · CD012493
Disease‐modifying treatments for primary autoimmune haemolytic anaemia
Liu, A-yP, Cheuk, DKL · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 2 · 28.6%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: adults with newly diagnosed warm AIHA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete haematological response at 12 months | RR 2.13 [1.34, 3.4] | 2 studies · 96 participants | Low Downgraded: risk of bias, imprecision |
Frequency of adverse events at two, six and 12 months | no estimate extracted | NR | No studies |
Partial haematological response at 12 months | RR 3 [0.13, 68.57] | 1 study · 32 participants | Very low Downgraded: risk of bias, imprecision |
Overall survival at six and 12 months | no estimate extracted | NR | No studies |
Relapse‐free survival at six and 12 months | no estimate extracted | NR | No studies |
RBC transfusion requirement after treatment at 12 months | RR 0.8 [0.26, 2.45] | 1 study · 32 participants | Very low Downgraded: risk of bias, imprecision |
QOL as measured by validated instruments at 12 months | no estimate extracted | NR | No studies |